HUE025528T2 - 1'-szubsztituált carba-nukleozid analógok antivirális kezeléshez - Google Patents

1'-szubsztituált carba-nukleozid analógok antivirális kezeléshez Download PDF

Info

Publication number
HUE025528T2
HUE025528T2 HUE09734175A HUE09734175A HUE025528T2 HU E025528 T2 HUE025528 T2 HU E025528T2 HU E09734175 A HUE09734175 A HU E09734175A HU E09734175 A HUE09734175 A HU E09734175A HU E025528 T2 HUE025528 T2 HU E025528T2
Authority
HU
Hungary
Prior art keywords
substituted
compound
alkyl
ora
methyl
Prior art date
Application number
HUE09734175A
Other languages
English (en)
Inventor
Thomas Butler
Aesop Cho
Choung U Kim
Oliver L Saunders
Lijun Zhang
Jay Parrish
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40887058&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE025528(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of HUE025528T2 publication Critical patent/HUE025528T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65744—Esters of oxyacids of phosphorus condensed with carbocyclic or heterocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • C07H5/06—Aminosugars
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Claims (2)

  1. :S?aikaáatoí
    1. Köptet ? ««mtivegyőlel:
    kápíaR; s vagy Mtiaik gyógymi^siseiukg $$1¾ $ *1: Π, OR* NíR'L N;, CN; NO;, S(0)aRs. r,*M*.. j , V^K ** > '»>K kJ 4M vx vWl"."v* 'S *'N * ' ^ 0 '* a' \ν«Λ ^tóXUáJV «.!&amp;*>"«.·· K'5- Cs)&amp;ííí.íííJÚ iCrCi;}-SA«bsít!i«ísk OkOO vssív K:iRCO:s)OkR; v&amp;gy prfsselylk: két R\ 0, b\ 0 vm:0 ^<^éé&amp;s *zm mm>kmi, h&amp; smt - 10 OíCQp· hí: t'gyüu va®É véve * gy§*§ ajady^áte-i^soi&amp;áasíf, te»#* sfetssak; Rí: OR'; m%*’>·:- N* CK >í% SíO^Rk -C{«0}&amp;u. «C(-DX>R|*, - |íO)Eí!t -$φ}&amp;η> 'Síö}(Orí;). .,..::^0^.. <CrC$.)»iM:> t«ír c0Kb®mmii íc&amp;mtewmii *ί*ι <&amp;$&amp;&amp;*#&amp; «μ, ^c^m, |.§ :(^v<ía)sáiii'Si:;5i3.sU aUciaiL vagy snU'C*· QsOlal '·&amp;¥? &amp; ***? R v*®' R ' rs3 íisyiití v&amp;saa*· vöv* OfCOm ásísáögyik a %gsfcül S, Ε -ν&amp;ρ ?; ; W^y\k. SÓ Rigg«tit>a|jl ir^C^OsJsIk!^. (CrC^lNftli ~:Cs>síi£«í OaJks^ísMskMk HPH>jRUv "C{-0}0ltu( b^9^,>ri^9Mj SiMé:\ m í>mor% ~%oum% vagy ok>>hr;'E!í; 0 i, 4j*oy&amp;l\ -Cí'-"OK)R;\ .a*0)NR*}RiS, ~C{“0}$R!\ -S(0)R''. SujsjR' .-^kííO^' j. v$(0>s(ORl'!}v v&amp;gy
    «Ufttyfc v vagy V'' . O, S< NR. Τ*)*». >*<»'. 'NíOROR;. vagy ^R·.; 2$ Ψ és W\ fe cgyön v^k vív* ^ v*&amp; W" β®** R * "d *** r -«t -Ψ- ésWS-«gyW' i&amp;ástka U?\# **'. vagy W* &amp; W* rogyik*. 9b«L«»>'· «gy k^í«t te botsán;
    képi st .shcíl: : mindegyik \ö: " m&amp;mm l ' ' SX ^ x χλγν \ N RR s ^ N !S(Ö>,vágySÍ:Ö)j; : ϊ^"·ί^γϊ|ζ v ^ &amp;§g«Ueftti! 0, S, v&amp;gy NA; M2 lg J vagy 2: aaksáegyík R* űsggitksiR Ry v&amp;gy a fesplsr.
    ahes: ^ mskifcgyjk Mis,: UH, hMU ö *&amp;gy; 1; M*fc 0. ι.ί,Μ,^δ.τΛΜΜ* v«n( ;: ffsjíiásgyjks' SiíggsPíífsuí íijCs>^ k. v·',. .^; \ yy \k ' " 'Γ', íX'^k- NiK- 4®, -$;o;x -¾¾¾ Moumi ^{«y^-oc^fpíí, ~ SC5(' Y!}R; ~S€K“V'}0&amp;< 'SGp Y'Jv^PXí .-^^Rjec^y·^ ♦ íg «KjfcNRt, -CN, -N> XG*> -ÖR, vsgy W3; vagy fc* ^8.v»sk m^M0? *#«^2<50'«», S-? aafeaiaxeos kiMx:;vá.kiS:0.'í gyvsví sikoi: jKíKífagysk'11 ííiggeUssüi H. íCj^-s? *iSt,K (i.VCy> s;}sib«s;R^U a&amp;&amp; (03·4··ί},**&amp;κι*1> s^í-C*.? «mh%ttÍKá)t aikftőii, &amp;VCs.> aM (CrC*) saa'&amp;tóstó 8&amp;ma. c, Qs vút Crt* fcZ»*«&amp;«éH arii, tv C>c. hítffi-isákb; Γ,Ό.κ sSuUihm&amp;k HiíaryVli, anííPki; vagy &amp;*ubszsteis!s. arüslkit; 20 \vs vxgy Wp X R^€(Y1;Rk-C(YiP^\..so^Rk^y^O;Wk.é5W> egy kaibeePhss vagy hvt'íi''"«slsb.ss, aVasW' JSggí*ie««l éasib'Kíuvy»»: 0*5 Ψ* cxopoxysk «xiadígyikX^a&amp;vX* XgeVVk O-R >v-N. .^adegyjk Rs bsJo*«>. K'ki:.R’\ N(k'!)OR!if N<, NÖ> NO*. CHO. CN, - CF^NRX -CH-'-';NHH'R:\ -CH«-Ni'ORi:}. 'CH{OR;i}5< <'(»0}:NRí!R!\ 4:XS)NE:\Rs\ CÍ"O}0E!\ 2S (CrCsteíkü, (CyC^^rr-l fCrQmimil (C^Q}kaírhoí-M^tM, Dpei&amp;UUm **uh*zümii ml opcks'^ksía-s síAlteto&amp;t haercatü. <tf"0){Cs*Q»Ikjl» "SíO)*{€i-C*}*lk&amp; sPRQX>s^> OK" v*$?. SR}Í; χχοά«ΑΥ&amp; ír vs.gy Η”' B, Ns ' N(R K?K xv ^ x ^ T40?, c*>. CH. -€tíH^!X .C!!*NHNR5\*CH«N(ORiKa «0*0»“* 'C{<í}NR;iH.l5; .-C{-S)NRiS.S:;, ssísáiftfvÉ R'1 m$y Éi:i S?( (0*Gf&amp;&amp;ií> i€^}xbsmíi> f^C^feiásGi**· β €t)k3íb^ikli!sikíS. «jfétóiSfcá sril spsiásá&amp;ss. s^ssz^lt .fec&amp;s&amp;saíü, « -^««Οχϋ,- v&amp;gy sn!PeG}s« SSÍ5&amp;X5&amp; ksgsxsIMR $&amp;y bi S3í&amp;$* §s$ f ksiy&amp;sMasss gyílsii fcs«íyss; « Umk^fsl·· -ex - S- vm í;hol :^j«4sgyife:CCrC,Jsia Cfc€s)§!fce«?i íCy ^gy «3£rof aMwik R* is M> r?s r4, i?; e* r« #:, $φ«Μ, t&amp;etoei»w férném m *m **»* *· feküí: Msgésg Sktefc CHS N>. N(R''}>. vsgy 01*; #.« a CC,-G}aíkú asm tenants μΛομο$» -Ov·*· vagy-KIO. a. Asr ?,· ig^^öíS sze&amp;nti
    ysgyüUs, sstóys?. * s#ks il MpNMritf ..... " , : :: ií : képiét 15 ásf Xs 0>p!JGs mkáégyisG G Y: Ό.:;: E i, vagy 2, igóiypost ssfastatt v®g5^2«í, gköí :: se I^R -., P[E )GK , mnmnx% QRihm$ywnf. 4. A* 1-5. M^etypontok '$ánnd>-<ke ugrimi vigyük? ah»· R* H vagy ΝΕ’Έ". 5. λ* !A^^yp^íokb«xs)é^^^naí{v«|?>iifeu&amp;hol E' Kvagy
    •NA ά-v? Íi.. ΛΧ {«$. igíaypjííök bé«8«$yR* *«>*»«* vegylUsg ultit A4 <2k\ N* Mog&amp;x Í-G *»*$> kxisSJímAE ^a;isbx£íj?tislí SS«G> eas?R> sa&amp;'satifcsáR «ten*·, vagy ««teiíG;?. snml ?. Aa I -E ^s^MfeR*>áná«lps« «.orsaí; vigyük &amp;hoi X" Őrt «» RJ é$ iV mtsKkgysk H $. M1". ^&amp;^8Rá.:Í«#e smk&amp; V«gy0)«k R* vagy E* koxö? lc.g»m *gy GR4. 9, -te í*$Pigé)Sy^tak báneéS??^ A£«».5» Nr»\«tei. 4Í*N λ N ''λΟ R" ^hoi R' H, GlsgéK- CK f4gyt>ps*ssÁü%'x á2«E*xi>n*M mm®?*......... •0. As ).* igényporM- oSraftlyü* «.««i'Hi νΦ»^,at»i R‘c«^' ssstakgyifeORx II. AK 1Ί0. Ig^yposíok bá«as^iR« mno® Vfigyaast, ah*>i R'«*K -'5^' 51 As M L 5|;ís^s*^í!í.M.ymeSy5ls« v§gy5ÍS«$, dsjl A' !i J3. Ak |-||. ígáöypjíiiok: béríádyöíe sassssU AsgySSíA skAi .A' C-H.
  2. 54, As 143. sg«s:v>«ostöl·' MrraAÍyöcé assrisá wgsAi shöl W K, m«H5s. CHjOii CHjF, M&amp;Siú^ vsgy essil. 3 i$. Az Ι-Ή. igesypaiiSvik Mixiidyiks sKexisA vegy&amp;At 4x4 W! és Ψ2 ötía^gyjfcs,. iSggeíissűi, s képiéi .bísopíst 1« As 144, igásytsojsok bán&amp;§l>'&amp;4 sssAxxti vsgyűfci, s&amp;»5
    ki VSS viisssivs &amp; 5®v'«tke,Aik kASíü:
    ahol 'A s ^ggíAsosSL ágy ksAés, 0, vagy CBA, •3 57, Aa 544, ;gásy|xsSökbáx!Sdyskux«xiA5ss^gyiii&amp;i, sM B.; &amp;. i A As ·. igsxsxypöSAxk bscsselyiks ss«ns5i vsgyiíkA sm4y
    vagy $6$%·;·- ..*$. l ' ->" "> '!VV mV \N\ - n \ 4, i , ,, <?< S{.»t < i '{sv ».s Ν' 50 íiiUtO'vTi-'X poUsfttsrí. pssíüáfipiiiiswf*lsk.h&amp;&amp; vagy srsrtrf siskhaí; '-«fi iík^ SO, : 4 4 kuxpspskk S:SS^|>'i^jSí§feaxg8 «ζ :í|«S|pipt# b&amp;SKsMy&amp;®íSa«ppíX Vagyaid "; vevápiásat; hatása* RurnttyKégtí &amp; gjtógy^testjfeg dfcíg&amp;áfe&amp;tö h^3x<Mr,ya%o&amp; it. Á M. j#s##í s^feá g^gv^^s^ií koötjkBfkdé, 'mely sombM'^0bb s0 íövékki t«á$íj*s 5 21 A. Ζ%,χφ%ρ>&amp; u^^^^^s^iéi^Mposski^ ahe< s további terápiás §«srki vaa váktsivs. pv«t^*’í;ékMI Má t^tporgM uttftfctWK'lf a&amp;ayjjp «n*i4$&amp; NS3 prukMa fcsbitaasfok, NSSs í?5h;bi>orok; &amp;S$t> ftdiméMa tnhfc&amp;ttsfe, iJallMíörbk, JkbSiin lahibitöíok, hepswvédök, Ht'V asm- wklá)*® Mmtixm P isis HCV fcdéséts. sí, ik-i-B. wntMű jppfcá|teám 10 Vágy vinxsos tnibkdó k«f?ksífí, 3r««iycs f/>ív?sgró&amp;a i«úsd vinsgs «k>;;utt. 24. A. 23, ®%0M sksl: a. wms&amp; élteiét β k&amp;vítkíSík:»; íilló vsGpöitíxd van kivéiiásxn<s ássps virus, sPpIP virus. kyiupi sM&amp;si vfefS»· $ψ&amp;8 ^^«A.’SÍfea: «ω&amp;Ββ* vln;S, Kmjin vírus. M'unsy Vslky euüph«Í5d< virus, St U»l «sspkgőíis: vlasra, Omsk Jsprprifisgikas Ma vims, fcökss vsasS Maiskp víma 1¾ vMs és 15 J-lspakisC vPis. 2&amp;, -M 34 igtmsjtORt sáenhá Vegyid &amp;ί:"* viÉ^,'::i8ÉI&amp;Í!^ HepííSfe üO virus okozza. 24,: μ 24,2$. spSypusp. kámgsyiP saödíks v*#Öfct íMhssKpásrsg «tv ísts&amp;lm^a legalább *gy árvItéMaMpés sssrsdagMssM, 20 22,: * M. |po;#í$í mstMí vep&amp;lsfc· ától δ w -WÉs k^é.'w « MvsteőkM SaMimd m^mMí *m Mtélmsmc hmks«««k ál»#rt» kfiííiSpK, » psiste »ífeé, Ν» iksl&amp;tek, Η» polios kkbdcrőM síiMglukéMMa * Mlíibei5.: dkteSsx trJ:dbijorok,.hsg5«íovéíii>k; HCV ftm-tsdcko»á inhibits! &amp; más gpgysasrp: HCV kezelésére.
HUE09734175A 2008-04-23 2009-04-22 1'-szubsztituált carba-nukleozid analógok antivirális kezeléshez HUE025528T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4726308P 2008-04-23 2008-04-23
US13944908P 2008-12-19 2008-12-19

Publications (1)

Publication Number Publication Date
HUE025528T2 true HUE025528T2 (hu) 2016-05-30

Family

ID=40887058

Family Applications (3)

Application Number Title Priority Date Filing Date
HUE15155479A HUE038946T2 (hu) 2008-04-23 2009-04-22 1'-szubsztituált carba-nukleozid analógok antivirális kezelésre
HUE09734175A HUE025528T2 (hu) 2008-04-23 2009-04-22 1'-szubsztituált carba-nukleozid analógok antivirális kezeléshez
HUS2000055C HUS2000055I1 (hu) 2008-04-23 2020-12-18 1'-szubsztituált carba-nukleozid analógok antivirális kezelésre

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HUE15155479A HUE038946T2 (hu) 2008-04-23 2009-04-22 1'-szubsztituált carba-nukleozid analógok antivirális kezelésre

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUS2000055C HUS2000055I1 (hu) 2008-04-23 2020-12-18 1'-szubsztituált carba-nukleozid analógok antivirális kezelésre

Country Status (32)

Country Link
US (5) US8008264B2 (hu)
EP (3) EP2937350B9 (hu)
JP (4) JP5425187B2 (hu)
KR (3) KR101645742B1 (hu)
CN (3) CN104262345B (hu)
AP (2) AP3076A (hu)
AR (1) AR071395A1 (hu)
AU (2) AU2009240630B2 (hu)
BR (2) BRPI0910455B8 (hu)
CA (2) CA2722084C (hu)
CO (2) CO6321235A2 (hu)
CY (4) CY1113647T1 (hu)
DK (3) DK2268642T3 (hu)
EA (2) EA019883B1 (hu)
EC (2) ECSP10010609A (hu)
ES (3) ES2398684T3 (hu)
HK (3) HK1152709A1 (hu)
HR (3) HRP20130048T1 (hu)
HU (3) HUE038946T2 (hu)
IL (2) IL208515A (hu)
LT (2) LT2937350T (hu)
ME (1) ME03089B (hu)
MX (2) MX2010011659A (hu)
NO (1) NO2937350T3 (hu)
NZ (2) NZ588400A (hu)
PL (3) PL2268642T3 (hu)
PT (3) PT2268642E (hu)
RS (2) RS54008B1 (hu)
SI (3) SI2280973T1 (hu)
TW (2) TW201334784A (hu)
WO (2) WO2009132135A1 (hu)
ZA (2) ZA201007713B (hu)

Families Citing this family (161)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EA200601591A1 (ru) 2000-05-26 2007-02-27 Айденикс (Кайман) Лимитед Применение рибонуклеозидных соединений для лечения флавивирусных и пестивирусных инфекций
EP1576138B1 (en) 2002-11-15 2017-02-01 Idenix Pharmaceuticals LLC. 2'-methyl nucleosides in combination with interferon and flaviviridae mutation
WO2009132135A1 (en) 2008-04-23 2009-10-29 Gilead Sciences, Inc. 1' -substituted carba-nucleoside analogs for antiviral treatment
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
EP2313102A2 (en) 2008-07-03 2011-04-27 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
EP2364314B1 (en) 2008-12-09 2014-03-12 Gilead Sciences, Inc. Modulators of toll-like receptors
BRPI0922508A8 (pt) 2008-12-23 2016-01-19 Pharmasset Inc Análogos de nucleosídeo
CA2748057C (en) 2008-12-23 2018-07-03 Pharmasset, Inc. Nucleoside phosphoramidates
JP5793084B2 (ja) 2008-12-23 2015-10-14 ギリアド ファーマセット エルエルシー プリンヌクレオシドの合成
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
DK2480559T3 (da) 2009-09-21 2013-08-05 Gilead Sciences Inc Fremgangsmåder og mellemprodukter til fremstillingen af 1'-cyano-carbanukleosid-analoger
US7973013B2 (en) 2009-09-21 2011-07-05 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
US8455451B2 (en) 2009-09-21 2013-06-04 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
NZ599402A (en) * 2009-09-21 2014-02-28 Gilead Sciences Inc 2’ -fluoro substituted carba-nucleoside analogs for antiviral treatment
MX2012004990A (es) 2009-10-30 2012-06-12 Janssen Pharmaceutica Nv Deribados de imidazo [1,2-b] pirimideazina y su uso como inhibidores de la enzima fosfodiesterasa 10.
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
CN102858790A (zh) * 2010-03-31 2013-01-02 吉利德制药有限责任公司 核苷氨基磷酸酯
TW201201815A (en) * 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
BR112013001267A2 (pt) * 2010-07-19 2016-05-17 Gilead Sciences Inc métodos para a preparação de pró-fármacos de fosforamidato diasteromericamente puro
CR20170278A (es) 2010-07-22 2017-09-29 Gilead Sciences Inc Métodos y compuestos para tratar infecciones virales por paramyxoviridae
TW201305185A (zh) * 2010-09-13 2013-02-01 Gilead Sciences Inc 用於抗病毒治療之２’－氟取代之碳－核苷類似物
KR101879887B1 (ko) * 2010-09-20 2018-07-18 길리애드 사이언시즈, 인코포레이티드 항바이러스 치료용 2'-플루오로 치환된 카바-누클레오시드 유사체
CA2812962C (en) 2010-09-22 2020-03-31 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
PT3042910T (pt) 2010-11-30 2019-04-16 Gilead Pharmasset Llc 2'-espiro-nucleósidos para utilização na terapia da hepatite c
CA2822037A1 (en) 2010-12-20 2012-06-28 Gilead Sciences, Inc. Methods for treating hcv
EP2691409B1 (en) 2011-03-31 2018-02-21 Idenix Pharmaceuticals LLC. Compounds and pharmaceutical compositions for the treatment of viral infections
US8877744B2 (en) * 2011-04-04 2014-11-04 Hoffmann-La Roche Inc. 1,4-Oxazepines as BACE1 and/or BACE2 inhibitors
US9156872B2 (en) 2011-04-13 2015-10-13 Merck Sharp & Dohme Corp. 2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
EP2696681B1 (en) * 2011-04-13 2018-10-03 Merck Sharp & Dohme Corp. 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
AU2012242978A1 (en) * 2011-04-13 2013-10-24 Merck Sharp & Dohme Corp. 2'-Cyano Substituted Nucleoside Derivatives and methods of use thereof for the treatment of viral diseases
BR112013033375B1 (pt) 2011-06-27 2022-05-10 Janssen Pharmaceutica N.V Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxa-lina, seu uso, composição farmacêutica que os compreende, processo de preparação dos mesmos, solução estéril e composto intermediário
WO2013009737A1 (en) 2011-07-13 2013-01-17 Merck Sharp & Dohme Corp. 5'-substituted nucleoside analogs and methods of use thereof for the treatment of viral diseases
US9416154B2 (en) 2011-07-13 2016-08-16 Merck Sharp & Dohme Corp. 5′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2013030750A1 (en) 2011-09-01 2013-03-07 Lupin Limited Antiviral compounds
EP2755983B1 (en) 2011-09-12 2017-03-15 Idenix Pharmaceuticals LLC. Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
SG10201602044WA (en) 2011-09-16 2016-04-28 Gilead Pharmassett Llc Methods For Treating HCV
KR20140071454A (ko) * 2011-09-30 2014-06-11 키네타, 인크. 항바이러스 화합물
US8507460B2 (en) 2011-10-14 2013-08-13 Idenix Pharmaceuticals, Inc. Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
EA201490836A1 (ru) * 2011-10-21 2014-11-28 Эббви Инк. Комбинационное лечение (например, с abt-072 или abt-333) с помощью daa для применения при лечении hcv
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
EP2812326A1 (en) 2012-02-10 2014-12-17 Lupin Limited Antiviral compounds with a dibenzooxaheterocycle moiety
EP3351552B1 (en) * 2012-03-13 2021-05-19 Gilead Sciences, Inc. 2'-substituted carba-nucleoside analogs for antiviral treatment
AU2013266393B2 (en) 2012-05-22 2017-09-28 Idenix Pharmaceuticals Llc D-amino acid compounds for liver disease
US9296778B2 (en) 2012-05-22 2016-03-29 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphate prodrugs for HCV infection
EP2852604B1 (en) 2012-05-22 2017-04-12 Idenix Pharmaceuticals LLC 3',5'-cyclic phosphoramidate prodrugs for hcv infection
EA027929B1 (ru) 2012-05-25 2017-09-29 Янссен Сайенсиз Айрлэнд Юси Нуклеозиды на основе урацила и спирооксетана
CN104411312B (zh) 2012-06-26 2018-03-06 詹森药业有限公司 包括pde2抑制剂例如1‑芳基‑4‑甲基‑[1,2,4]三唑[4,3‑a]‑喹喔啉化合物和pde10抑制剂的用于在治疗神经病学障碍或代谢障碍中使用的组合
MX362197B (es) 2012-07-09 2019-01-08 Janssen Pharmaceutica Nv Derivados de imidazo[1,2-b]piridazina e imidazo[1,2-a]pirazina como inhibidores de la fosfodiesterasa 10; y el uso de los mismos en el tratamiento de trastornos neurológicos, psiquiátricos y metabólicos.
WO2014035140A2 (en) * 2012-08-30 2014-03-06 Kainos Medicine, Inc. Compounds and compositions for modulating histone methyltransferase activity
WO2014042433A2 (en) * 2012-09-14 2014-03-20 Kainos Medicine, Inc. Compounds and compositions for modulating adenosine a3 receptor activity
WO2014052638A1 (en) * 2012-09-27 2014-04-03 Idenix Pharmaceuticals, Inc. Esters and malonates of sate prodrugs
ES2674980T3 (es) 2012-10-08 2018-07-05 Idenix Pharmaceuticals Llc Análogos de 2'-cloro nucleósidos para infección por VHC
WO2014059901A1 (en) 2012-10-17 2014-04-24 Merck Sharp & Dohme Corp. 2'-cyano substituted nucleoside derivatives and methods of use thereof for treatment of viral diseases
AR092959A1 (es) 2012-10-17 2015-05-06 Merck Sharp & Dohme Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
WO2014059902A1 (en) 2012-10-17 2014-04-24 Merck Sharp & Dohme Corp. 2'-disubstituted substituted nucleoside derivatives and methods of use thereof for treatment of viral diseases
US10723754B2 (en) 2012-10-22 2020-07-28 Idenix Pharmaceuticals Llc 2′,4′-bridged nucleosides for HCV infection
US9732111B2 (en) 2012-11-19 2017-08-15 Merck Sharp & Dohme Corp. 2′-alkynyl substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
EP2935304A1 (en) 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
CA2852867C (en) 2013-01-31 2016-12-06 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
US10034893B2 (en) 2013-02-01 2018-07-31 Enanta Pharmaceuticals, Inc. 5, 6-D2 uridine nucleoside/tide derivatives
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
US9309275B2 (en) 2013-03-04 2016-04-12 Idenix Pharmaceuticals Llc 3′-deoxy nucleosides for the treatment of HCV
EP2970357A1 (en) 2013-03-13 2016-01-20 IDENIX Pharmaceuticals, Inc. Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
WO2014165542A1 (en) 2013-04-01 2014-10-09 Idenix Pharmaceuticals, Inc. 2',4'-fluoro nucleosides for the treatment of hcv
US10005779B2 (en) 2013-06-05 2018-06-26 Idenix Pharmaceuticals Llc 1′,4′-thio nucleosides for the treatment of HCV
WO2014204831A1 (en) 2013-06-18 2014-12-24 Merck Sharp & Dohme Corp. Cyclic phosphonate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
EP3027636B1 (en) 2013-08-01 2022-01-05 Idenix Pharmaceuticals LLC D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
UA119050C2 (uk) * 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
EP3074399A1 (en) * 2013-11-27 2016-10-05 Idenix Pharmaceuticals LLC 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
WO2015143712A1 (en) 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
WO2015161137A1 (en) 2014-04-16 2015-10-22 Idenix Pharmaceuticals, Inc. 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
WO2015166370A1 (en) 2014-04-28 2015-11-05 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
NZ728072A (en) 2014-07-11 2018-06-29 Gilead Sciences Inc Modulators of toll-like receptors for the treatment of hiv
TWI678369B (zh) * 2014-07-28 2019-12-01 美商基利科學股份有限公司 用於治療呼吸道合胞病毒感染之噻吩並［３,２-ｄ］嘧啶、呋喃並［３,２-ｄ］嘧啶及吡咯並［３,２-ｄ］嘧啶化合物類
WO2016023522A2 (en) 2014-08-15 2016-02-18 Merck Sharp & Dohme Corp. Substituted phosphoramidate compounds and uses thereof
TWI673283B (zh) 2014-08-21 2019-10-01 美商基利科學股份有限公司 ２’－氯胺基嘧啶酮及嘧啶二酮核苷類
WO2016033164A1 (en) 2014-08-26 2016-03-03 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
JP2017526730A (ja) 2014-09-16 2017-09-14 ギリアード サイエンシーズ， インコーポレイテッド Ｔｏｌｌ様受容体モジュレーターの固体形態
TWI740546B (zh) 2014-10-29 2021-09-21 美商基利科學股份有限公司 製備核糖苷的方法
WO2016069975A1 (en) * 2014-10-31 2016-05-06 Cocrystal Pharma, Inc. 2',2'-dihalo nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
US9718851B2 (en) 2014-11-06 2017-08-01 Enanta Pharmaceuticals, Inc. Deuterated nucleoside/tide derivatives
US9732110B2 (en) 2014-12-05 2017-08-15 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
CA2969372C (en) 2014-12-15 2023-05-16 Emory University Phosphoramidates for the treatment of hepatitis b virus
SG11201705069YA (en) 2014-12-26 2017-07-28 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
EA039561B1 (ru) * 2015-01-20 2022-02-10 Джилид Сайэнс, Инк. Соединения для лечения вирусных инфекций filoviridae
UA124966C2 (uk) 2015-03-06 2021-12-22 Атеа Фармасеутікалс, Інк. <font face="Symbol">b</font>-D-2'-ДЕЗОКСИ-2'-<font face="Symbol">a</font>-ФТОР-2'-<font face="Symbol">b</font>-C-ЗАМІЩЕНІ-2-МОДИФІКОВАНІ-N<sup>6</sup>-ЗАМІЩЕНІ ПУРИНОВІ НУКЛЕОТИДИ ДЛЯ ЛІКУВАННЯ ВИКЛИКАНИХ HCV ЗАХВОРЮВАНЬ
WO2016160646A1 (en) 2015-04-02 2016-10-06 Merck Sharp & Dohme Corp. Process for making phosphoramidate protected nucleoside compounds
MX2017013956A (es) 2015-05-01 2018-09-05 Cocrystal Pharma Inc Analogos de nucleosidos para el tratamiento de la familia de virus flaviviridae y cancer.
EP4001283A1 (en) * 2015-05-12 2022-05-25 F. Hoffmann-La Roche AG Substituted aminothiazolopyrimidinedione derivatives for the treatment and prophylaxis of virus infection
JP6949002B6 (ja) 2015-08-05 2021-11-17 メトロ インターナショナル バイオテック，エルエルシー ニコチンアミドモノヌクレオチド誘導体及びそれらの使用
SG10202001878WA (en) 2015-09-16 2020-04-29 Gilead Sciences Inc Methods for treating arenaviridae and coronaviridae virus infections
CN108289931B (zh) 2015-09-23 2022-10-11 默沙东公司 4’-取代的核苷逆转录酶抑制剂及其制备
TWI740910B (zh) 2016-03-09 2021-10-01 美商艾洛斯生物製藥公司 非環抗病毒劑
KR102558066B1 (ko) 2016-03-28 2023-07-25 인사이트 코포레이션 Tam 억제제로서 피롤로트리아진 화합물
WO2017184668A1 (en) * 2016-04-20 2017-10-26 Gilead Sciences, Inc. Methods for treating flaviviridae virus infections
WO2017184670A2 (en) 2016-04-22 2017-10-26 Gilead Sciences, Inc. Methods for treating zika virus infections
KR20190057277A (ko) 2016-06-24 2019-05-28 에모리 유니버시티 B형 간염 바이러스 치료용 포스포아미데이트
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
LU100724B1 (en) 2016-07-14 2018-07-31 Atea Pharmaceuticals Inc Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
TW201811339A (zh) * 2016-08-12 2018-04-01 美商艾洛斯生物製藥公司 經取代之核苷、核苷酸及其類似物
EP3865136A1 (en) 2016-09-07 2021-08-18 ATEA Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for corona virus treatment
WO2018129039A1 (en) 2017-01-04 2018-07-12 President And Fellows Of Harvard College Modulating nudix homology domain (nhd) with nicotinamide mononucleotide analogs and derivatives of same
KR20230151050A (ko) 2017-02-01 2023-10-31 아테아 파마슈티컬즈, 인크. C형 간염 바이러스를 치료하기 위한 뉴클레오티드 헤미-술페이트 염
KR102460968B1 (ko) 2017-03-14 2022-11-01 길리애드 사이언시즈, 인코포레이티드 고양이 코로나바이러스 감염의 치료 방법
WO2018204198A1 (en) 2017-05-01 2018-11-08 Gilead Sciences, Inc. Crystalline forms of (s) 2 ethylbutyl 2 (((s) (((2r,3s,4r,5r) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
CA3077489A1 (en) 2017-07-11 2019-01-17 Gilead Sciences, Inc. Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections
TWI624264B (zh) * 2017-08-11 2018-05-21 景鑫生物科技股份有限公司 南洋山蘇水萃物的用途
CR20200126A (es) * 2017-09-18 2020-07-11 Janssen Biopharma Inc Nucleósidos sustituidos, nucleótidos y análogos de estos
EP3706762A4 (en) 2017-12-07 2021-09-01 Emory University N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTIVIRAL USES IN RELATION TO IT
US11040975B2 (en) 2017-12-08 2021-06-22 Merck Sharp & Dohme Corp. Carbocyclic nucleoside reverse transcriptase inhibitors
CA3087192A1 (en) * 2017-12-27 2019-07-04 Raymond F. Schinazi Combined modalities for nucleosides and/or nadph oxidase (nox) inhibitors as myeloid-specific antiviral agents
TW202012001A (zh) 2018-04-10 2020-04-01 美商亞堤製藥公司 C型肝炎病毒(hcv)感染硬化之患者的治療
US11787833B2 (en) 2019-05-09 2023-10-17 Aligos Therapeutics, Inc. Modified cyclic dinucleoside compounds as sting modulators
CN110724174B (zh) * 2019-09-10 2021-02-05 广州六顺生物科技股份有限公司 吡咯并三嗪类化合物、组合物及其应用
CA3163424A1 (en) 2020-01-27 2021-08-05 Gilead Sciences, Inc. Methods for treating sars cov-2 infections
CN113214262B (zh) * 2020-02-05 2023-07-07 华创合成制药股份有限公司 一种含有胍基的化合物及其制备方法和用途
CN113214334A (zh) * 2020-02-05 2021-08-06 华创合成制药股份有限公司 用于治疗病毒感染的化合物及其制备方法和用途
TWI791193B (zh) 2020-02-18 2023-02-01 美商基利科學股份有限公司 抗病毒化合物
US20210292348A1 (en) 2020-02-18 2021-09-23 Gilead Sciences, Inc. Antiviral compounds
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
CN113292565B (zh) * 2020-02-24 2023-01-31 浙江森科建设有限公司 核苷类化合物及其制备方法和应用
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
CN111269248A (zh) * 2020-03-05 2020-06-12 江苏福瑞康泰药业有限公司 一种核苷氨基磷酸酯类药物母液回收的新方法
JP2023516087A (ja) 2020-03-12 2023-04-17 ギリアード サイエンシーズ， インコーポレイテッド １’－シアノヌクレオシドを調製する方法
CA3169348A1 (en) 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
TW202143949A (zh) * 2020-03-22 2021-12-01 盈擘醫藥股份有限公司 用於預防或暴露後治療感染或呼吸疾病的抗病毒組成物
WO2021202669A2 (en) 2020-04-01 2021-10-07 Reyoung Corporation Nucleoside and nucleotide conjugate compounds and uses thereof
KR20220164784A (ko) 2020-04-06 2022-12-13 길리애드 사이언시즈, 인코포레이티드 1'-시아노 치환된 카르바뉴클레오시드 유사체의 흡입 제형
CN112778310A (zh) * 2020-04-20 2021-05-11 中国科学院上海药物研究所 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用
TW202203941A (zh) 2020-05-29 2022-02-01 美商基利科學股份有限公司 瑞德西韋之治療方法
CR20220675A (es) 2020-06-24 2023-02-15 Gilead Sciences Inc Análogos de nucleósido de 1´- ciano y usos de los mismos
WO2022029704A1 (en) 2020-08-06 2022-02-10 Richter Gedeon Nyrt. Remdesivir intermediates
CN111956630A (zh) * 2020-08-20 2020-11-20 大连理工大学 一种瑞德西韦供雾化器用的液体制剂、制备方法及其应用
KR20230057411A (ko) 2020-08-27 2023-04-28 길리애드 사이언시즈, 인코포레이티드 바이러스 감염 치료를 위한 화합물 및 방법
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
WO2022098371A1 (en) * 2020-11-09 2022-05-12 Yan Matthew Prodrugs of 1'-substituted carba-nucleoside analogues for antiviral treatment
WO2022103758A1 (en) 2020-11-11 2022-05-19 Gilead Sciences, Inc. METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES
CN112494500B (zh) * 2020-11-26 2022-01-11 北京箭牧科技有限公司 瑞德西韦在制备治疗抗肿瘤药物心脏毒性药物中的应用
CN114621229A (zh) * 2020-12-11 2022-06-14 嘉兴金派特生物科技有限公司 治疗或预防猫传染性腹膜炎的化合物或组合物
CN112592348B (zh) * 2020-12-21 2022-03-08 南京法恩化学有限公司 一种4-氨基吡咯并[2,1-f][1,2,4]三嗪的制备方法
CN116874490A (zh) * 2020-12-30 2023-10-13 南方科技大学 化合物atv014或其药学可接受的盐及其药物组合物
WO2022221514A1 (en) 2021-04-16 2022-10-20 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
KR20230001208A (ko) 2021-06-28 2023-01-04 동아대학교 산학협력단 오각고리 염기를 포함하는 비고리형 핵산 모방체
CN115703796A (zh) * 2021-08-09 2023-02-17 苏州恩泰新材料科技有限公司 一种瑞德西韦重要中间体制备方法
US20230212148A1 (en) 2021-12-03 2023-07-06 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
US20230203071A1 (en) 2021-12-03 2023-06-29 Zhimin Du Therapeutic compounds for hiv virus infection
US11787825B2 (en) 2021-12-03 2023-10-17 Gilead Sciences, Inc. Therapeutic compounds for HIV virus infection
TW202400185A (zh) 2022-03-02 2024-01-01 美商基利科學股份有限公司 用於治療病毒感染的化合物及方法
TW202400172A (zh) 2022-04-06 2024-01-01 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
CN114437159B (zh) * 2022-04-11 2022-06-28 佛山市晨康生物科技有限公司 一种环状碳酸酯核苷类化合物及其应用
WO2023207942A1 (zh) * 2022-04-25 2023-11-02 北京沐华生物科技有限责任公司 用于治疗或预防冠状病毒感染的核苷类药物及其用途
WO2024006461A1 (en) * 2022-06-30 2024-01-04 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
US20240034724A1 (en) 2022-07-01 2024-02-01 Gilead Sciences, Inc. Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
US20240083984A1 (en) 2022-08-26 2024-03-14 Gilead Sciences, Inc. Dosing and scheduling regimen for broadly neutralizing antibodies
WO2024076915A1 (en) 2022-10-04 2024-04-11 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use
WO2024088184A1 (en) * 2022-10-23 2024-05-02 Shanghai Curegene Pharmaceutical Co., Ltd. Anti-feline-coronavirus compounds and uses thereof
WO2024088183A1 (en) * 2022-10-23 2024-05-02 Shanghai Curegene Pharmaceutical Co., Ltd. Anticoronviral compounds and compositions and uses thereof
CN115819423A (zh) * 2022-11-29 2023-03-21 武汉大学 一种瑞德西韦或其中间体的protac化合物及其制备方法与抗ev71的应用
CN116217621B (zh) * 2023-04-26 2023-08-11 北京沐华生物科技有限责任公司 一种核苷类双前药、合成方法及应用

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) * 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
JPS59141856A (ja) 1983-02-02 1984-08-14 Fuji Electric Co Ltd Ｆｓ変復調方式
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
DK0533833T3 (da) 1990-06-13 1996-04-22 Arnold Glazier Phosphorprolægemidler
ATE167679T1 (de) * 1990-09-14 1998-07-15 Acad Of Science Czech Republic Wirkstoffvorläufer von phosphonaten
US6887707B2 (en) 1996-10-28 2005-05-03 University Of Washington Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
DE69936998T2 (de) 1998-10-16 2008-05-21 Merck Sharp & Dohme Ltd., Hoddesdon Pyrazolotriazinderivate als gaba-rezeptorliganden
DE19912636A1 (de) * 1999-03-20 2000-09-21 Aventis Cropscience Gmbh Bicyclische Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide und pharmazeutische Mittel
AU7490600A (en) 1999-09-15 2001-04-17 Biocryst Pharmaceuticals, Inc. Inhibiting t-cell proliferation
EP1225899A2 (en) 1999-11-04 2002-07-31 Virochem Pharma Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
CN1427722A (zh) 2000-02-18 2003-07-02 希拉生物化学股份有限公司 用核苷类似物治疗或预防黄病毒感染的方法
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EA200601591A1 (ru) * 2000-05-26 2007-02-27 Айденикс (Кайман) Лимитед Применение рибонуклеозидных соединений для лечения флавивирусных и пестивирусных инфекций
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
BR0114837A (pt) 2000-10-18 2006-05-09 Pharmasset Ltd nucleosìdeos modificados para tratamento de infecções viróticas e proliferação celular anormal
WO2002057287A2 (en) * 2001-01-22 2002-07-25 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
WO2003026675A1 (en) * 2001-09-28 2003-04-03 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside
AT410792B (de) 2001-12-28 2003-07-25 Dsm Fine Chem Austria Gmbh Verfahren zur herstellung von geschützten, enantiomeren-angereicherten cyanhydrinen durch in-situ-derivatisierung
CA2477741A1 (en) 2002-02-28 2003-09-04 Biota, Inc. Nucleotide mimics and their prodrugs
WO2003073989A2 (en) 2002-02-28 2003-09-12 Biota, Inc. Nucleoside 5'-monophosphate mimics and their prodrugs
US20040138170A1 (en) 2002-03-06 2004-07-15 Montgomery John A. Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
GB0210127D0 (en) 2002-05-02 2002-06-12 Merck Sharp & Dohme Therapeutic agents
GB0210124D0 (en) 2002-05-02 2002-06-12 Merck Sharp & Dohme Therapeutic agents
CA2484921A1 (en) 2002-05-06 2003-11-13 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis c virus infection
US20050250728A1 (en) 2002-05-23 2005-11-10 Shanta Bantia Enhancing the efficacy of reverse transcriptase and dna polymerase inhibitors (nucleoside analogs) using pnp inhibitors and/or 2'-deoxyguanosine and/or prodrug thereof
EP1576138B1 (en) 2002-11-15 2017-02-01 Idenix Pharmaceuticals LLC. 2'-methyl nucleosides in combination with interferon and flaviviridae mutation
DK1628685T3 (da) 2003-04-25 2011-03-21 Gilead Sciences Inc Antivirale phosphonatanaloge
WO2005020885A2 (en) 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
BRPI0412849A (pt) 2003-07-25 2006-09-26 Idenix Cayman Ltd compostos, composições e usos de análogos de nucleosìdeo de purina para o tratamento de flaviviridae, incluindo hepatite c
JP2007504152A (ja) 2003-08-27 2007-03-01 ビオタ， インコーポレイテッド 治療剤としての新規三環ヌクレオシドまたはヌクレオチド
AU2005254057B2 (en) 2004-06-15 2011-02-17 Isis Pharmaceuticals, Inc. C-purine nucleoside analogs as inhibitors of RNA-dependent RNA viral polymerase
WO2006002231A1 (en) 2004-06-22 2006-01-05 Biocryst Pharmaceuticals, Inc. Aza nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
PT3109244T (pt) 2004-09-14 2019-06-04 Gilead Pharmasset Llc ¿preparação de ribofuranosil pirimidinas e purinas 2¿-fluoro-2¿-alquil substituídas ou outras opcionalmente substituídas e os seus derivados
CA2584367A1 (en) 2004-10-21 2006-06-22 Merck & Co., Inc. Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of rna-dependent rna viral infection
CN101043893A (zh) 2004-10-21 2007-09-26 默克公司 治疗RNA－依赖性RNA病毒感染的氟化吡咯并[2,3－d]嘧啶核苷
WO2006050161A2 (en) 2004-10-29 2006-05-11 Biocryst Pharmaceuticals, Inc. Therapeutic furopyrimidines and thienopyrimidines
EP1858889A1 (en) 2005-03-08 2007-11-28 Biota Scientific Management Pty. Ltd. Bicyclic nucleosides and nucleotides as therapeutic agents
WO2006104945A2 (en) 2005-03-29 2006-10-05 Biocryst Pharmaceuticals, Inc. Hepatitis c therapies
WO2006121820A1 (en) 2005-05-05 2006-11-16 Valeant Research & Development Phosphoramidate prodrugs for treatment of viral infection
WO2007027248A2 (en) 2005-05-16 2007-03-08 Valeant Research & Development 3', 5' - cyclic nucleoside analogues for treatment of hcv
CN101321775B (zh) 2005-10-03 2012-05-23 大学健康网络 用于治疗疟疾的odcase抑制剂
US8431695B2 (en) 2005-11-02 2013-04-30 Bayer Intellectual Property Gmbh Pyrrolo[2,1-f][1,2,4]triazin-4-ylamines IGF-1R kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
CN101466710B (zh) 2005-12-02 2013-05-29 拜尔健康护理有限责任公司 用于治疗与血管生成有关的过度增殖性病症和疾病的取代的4-氨基-吡咯并三嗪衍生物
PE20070855A1 (es) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
WO2007097991A2 (en) 2006-02-16 2007-08-30 Pharmasset, Inc. Methods and kits for dosing of antiviral agents
AR061024A1 (es) 2006-05-22 2008-07-30 Novartis Ag Maleato de 5-amino-3- (2'3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d] pirimidin-2-ona.
WO2008005542A2 (en) * 2006-07-07 2008-01-10 Gilead Sciences, Inc., Antiviral phosphinate compounds
US20080161324A1 (en) 2006-09-14 2008-07-03 Johansen Lisa M Compositions and methods for treatment of viral diseases
ITBO20060683A1 (it) 2006-10-03 2008-04-04 Sympak Corazza S P A Dispositivo per il raggruppamento di confezioni.
JP2010513484A (ja) 2006-12-20 2010-04-30 メルク・シャープ・エンド・ドーム・コーポレイション Ｒｎａ依存性ｒｎａウイルス感染治療用ヌクレオシド環状ホスホロアミデート
US20080261913A1 (en) 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
EP2124555B1 (en) 2007-01-05 2015-07-08 Merck Sharp & Dohme Corp. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
MX2009007333A (es) 2007-01-12 2009-08-31 Biocryst Pharm Inc Analogos de nucleosidos antivirales.
EP2125819B1 (en) 2007-03-21 2014-10-22 Bristol-Myers Squibb Company Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
DK2155758T3 (da) 2007-05-10 2012-11-05 Biocryst Pharm Inc Tetrahydrofuro[3,4-d]dioxolanforbindelser til anvendelse i behandlingen af virusinfektioner og cancer
CN100532388C (zh) 2007-07-16 2009-08-26 郑州大学 2’-氟-4’-取代-核苷类似物、其制备方法及应用
TW200942243A (en) 2008-03-05 2009-10-16 Biocryst Pharm Inc Antiviral therapeutic agents
US7863291B2 (en) 2008-04-23 2011-01-04 Bristol-Myers Squibb Company Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
WO2009132135A1 (en) 2008-04-23 2009-10-29 Gilead Sciences, Inc. 1' -substituted carba-nucleoside analogs for antiviral treatment
WO2010036407A2 (en) 2008-05-15 2010-04-01 Biocryst Pharmaceuticals, Inc. Antiviral nucleoside analogs
EP2313102A2 (en) 2008-07-03 2011-04-27 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
CA2751277C (en) 2009-02-10 2018-10-30 Gilead Sciences, Inc. Carba-nucleoside analogs for antiviral treatment
JP5766687B2 (ja) 2009-03-24 2015-08-19 バイオクリスト ファーマスーティカルズ，インコーポレイテッドＢｉｏｃｒｙｓｔ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． ７−［（３ｒ，４ｒ）−３−ヒドロキシ−４−ヒドロキシメチル−ピロリジン−１−イルメチル］−３，５−ジヒドロ−ピロロ［３，２−ｄ］ピリミジン−４−オンの有用な医薬塩
TWI598358B (zh) * 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
US8455451B2 (en) 2009-09-21 2013-06-04 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
DK2480559T3 (da) 2009-09-21 2013-08-05 Gilead Sciences Inc Fremgangsmåder og mellemprodukter til fremstillingen af 1'-cyano-carbanukleosid-analoger
NZ599402A (en) 2009-09-21 2014-02-28 Gilead Sciences Inc 2’ -fluoro substituted carba-nucleoside analogs for antiviral treatment
US7973013B2 (en) 2009-09-21 2011-07-05 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
JP5872539B2 (ja) 2010-03-31 2016-03-01 ギリアド ファーマセット エルエルシー プリンヌクレオシドホスホルアミダート
TW201201815A (en) 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
BR112013001267A2 (pt) 2010-07-19 2016-05-17 Gilead Sciences Inc métodos para a preparação de pró-fármacos de fosforamidato diasteromericamente puro
CR20170278A (es) 2010-07-22 2017-09-29 Gilead Sciences Inc Métodos y compuestos para tratar infecciones virales por paramyxoviridae
TW201305185A (zh) 2010-09-13 2013-02-01 Gilead Sciences Inc 用於抗病毒治療之２’－氟取代之碳－核苷類似物
KR101879887B1 (ko) 2010-09-20 2018-07-18 길리애드 사이언시즈, 인코포레이티드 항바이러스 치료용 2'-플루오로 치환된 카바-누클레오시드 유사체
CA2813783C (en) 2010-10-15 2019-01-22 Shanta Bantia Methods and compositions for inhibition of polymerase

Also Published As

Publication number Publication date
TW201334784A (zh) 2013-09-01
HK1152709A1 (en) 2012-03-09
SI2268642T1 (sl) 2015-05-29
CO6300958A2 (es) 2011-07-21
BRPI0910455A2 (pt) 2018-02-14
IL208701A0 (en) 2010-12-30
AU2009240642B2 (en) 2013-08-29
KR20110004883A (ko) 2011-01-14
NZ588400A (en) 2012-08-31
EA201071170A1 (ru) 2011-08-30
KR101645742B1 (ko) 2016-08-04
DK2937350T3 (en) 2018-04-23
CY1113647T1 (el) 2016-06-22
LT2937350T (lt) 2018-04-10
CA2722084A1 (en) 2009-10-29
CY2020044I1 (el) 2021-03-12
NZ588670A (en) 2012-08-31
TWI401084B (zh) 2013-07-11
HK1154010A1 (en) 2012-04-20
NO2937350T3 (hu) 2018-06-09
CN102015714A (zh) 2011-04-13
US20090317361A1 (en) 2009-12-24
ES2398684T3 (es) 2013-03-21
EP2937350A1 (en) 2015-10-28
JP2014040471A (ja) 2014-03-06
JP2011521903A (ja) 2011-07-28
EA020659B1 (ru) 2014-12-30
EA019883B1 (ru) 2014-07-30
ECSP10010609A (es) 2010-12-30
AU2009240630B2 (en) 2013-07-18
ECSP10010618A (es) 2011-03-31
WO2009132135A1 (en) 2009-10-29
AU2009240642A1 (en) 2009-10-29
LTPA2020539I1 (lt) 2021-01-11
BRPI0910455B8 (pt) 2021-05-25
CA2722177A1 (en) 2009-10-29
PT2268642E (pt) 2015-06-02
HUS2000055I1 (hu) 2021-01-28
ES2665272T3 (es) 2018-04-25
CY1120366T1 (el) 2019-07-10
EP2937350B9 (en) 2022-08-17
ZA201008008B (en) 2011-07-27
EP2280973A1 (en) 2011-02-09
KR101681559B1 (ko) 2016-12-01
SI2280973T1 (sl) 2013-03-29
AU2009240630A1 (en) 2009-10-29
EP2268642A1 (en) 2011-01-05
HUE038946T2 (hu) 2018-12-28
LTC2937350I2 (lt) 2022-05-10
AP2010005439A0 (en) 2010-10-31
IL208515A0 (en) 2010-12-30
US20110293563A1 (en) 2011-12-01
AP3237A (en) 2015-04-30
JP5425187B2 (ja) 2014-02-26
HK1216750A1 (zh) 2016-12-02
MX2010011659A (es) 2010-11-30
EP2280973B1 (en) 2012-11-28
CA2722084C (en) 2016-08-23
USRE46762E1 (en) 2018-03-27
BRPI0910455B1 (pt) 2020-10-27
RS54008B1 (en) 2015-10-30
US8012941B2 (en) 2011-09-06
AP3076A (en) 2014-12-31
MX2010011661A (es) 2010-11-30
WO2009132123A1 (en) 2009-10-29
US8853171B2 (en) 2014-10-07
EA201071128A1 (ru) 2011-08-30
CO6321235A2 (es) 2011-09-20
KR20160138591A (ko) 2016-12-05
KR20110005888A (ko) 2011-01-19
ZA201007713B (en) 2011-07-27
ES2536193T3 (es) 2015-05-21
CN104262345B (zh) 2017-06-23
US20130344028A2 (en) 2013-12-26
ME03089B (me) 2019-01-20
US8318682B2 (en) 2012-11-27
IL208515A (en) 2016-04-21
US20100021425A1 (en) 2010-01-28
PL2268642T3 (pl) 2015-08-31
US8008264B2 (en) 2011-08-30
TW201002331A (en) 2010-01-16
CN102015714B (zh) 2014-09-24
EP2268642B1 (en) 2015-02-25
CY1116425T1 (el) 2017-02-08
CA2722177C (en) 2016-08-16
HRP20130048T1 (hr) 2013-02-28
CN102046626A (zh) 2011-05-04
PT2280973E (pt) 2013-02-04
IL208701A (en) 2016-03-31
HRP20180572T1 (hr) 2018-05-18
HRP20150359T1 (hr) 2015-05-22
US20130034521A1 (en) 2013-02-07
CY2020044I2 (el) 2021-03-12
EP2937350B1 (en) 2018-01-10
JP2011518835A (ja) 2011-06-30
DK2268642T3 (en) 2015-05-26
PT2937350T (pt) 2018-04-16
PL2937350T3 (pl) 2018-06-29
CN104262345A (zh) 2015-01-07
DK2280973T3 (da) 2013-03-04
AP2010005414A0 (en) 2010-10-31
SI2937350T1 (en) 2018-05-31
JP5425186B2 (ja) 2014-02-26
PL2280973T3 (pl) 2013-05-31
KR101856404B1 (ko) 2018-05-09
JP2014012739A (ja) 2014-01-23
BRPI0911410A2 (pt) 2015-10-06
AR071395A1 (es) 2010-06-16
RS57092B1 (sr) 2018-06-29

Similar Documents

Publication Publication Date Title
USRE46762E1 (en) 1′-substituted carba-nucleoside analogs for antiviral treatment
DK2396340T3 (en) Carbanucleosidanaloge to antiviral therapy
AU2016250419B2 (en) 1&#39; -substituted carba-nucleoside analogs for antiviral treatment
AU2013216595B2 (en) 1&#39; -substituted carba-nucleoside analogs for antiviral treatment